Summit Therapeutics Inc. (SMMT) has a consensus analyst rating of Buy, based on 20 analysts covering the stock. Of those, 15 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for SMMT is $26.00, representing a +24.7% upside from the current price of $20.85. Price targets range from a low of $16.00 to a high of $40.00.
